Stay updated with breaking news from Iontech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced positive data from the Phase 2/3 trial evaluating the safety, tolerability, and immunogenicity of Omicron-adapted COVID-19
25.06.2022 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of ...
Children 6 months and older can now get their COVID-19 vaccine, a federal group decided...
In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in
What to know about COVID vaccines for young children